This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Apr 24;397(10284):1523-1524.

doi: 10.1016/S0140-6736(21)00873-4.

Nanobody cytokine blockers in psoriasis

Affiliations

PMID: 33894820
DOI: 10.1016/S0140-6736(21)00873-4

Comment

Nanobody cytokine blockers in psoriasis

Diana Rubel. Lancet. 2021.

. 2021 Apr 24;397(10284):1523-1524.

doi: 10.1016/S0140-6736(21)00873-4.

Author

Affiliation

¹ Australian National University, Canberra, ACT 2605, Australia. Electronic address: diana@wodendermatology.com.au.

PMID: 33894820
DOI: 10.1016/S0140-6736(21)00873-4

No abstract available

PubMed Disclaimer

Comment on

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Papp KA, Weinberg MA, Morris A, Reich K. Papp KA, et al. Lancet. 2021 Apr 24;397(10284):1564-1575. doi: 10.1016/S0140-6736(21)00440-2. Lancet. 2021. PMID: 33894834 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information